Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. Precision's Jenny Chen, Sam Keeping and Julie Park joined other experts to conduct a large, retrospective chart review of European patients with R/R MCL with prior BTKi therapy (SCHOLAR-2).